DiaMedica Therapeutics Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 9.52 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 513.37M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Details
| Name | DiaMedica Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 35 |
| Founded | 2000 |
| Ceo | Dietrich Pauls |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | CA25253X2077 |
| Cusip | 25253X207 |
| Cik | 0001401040 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dietrich John Pauls MBA | President, Chief Executive Officer and Director |
| Scott Kellen CPA | Chief Financial Officer and Corporate Secretary |
| Dr. Julie Krop M.D. | Chief Medical Officer |
| Dr. Ambarish Shah Ph.D. | Chief Technology Officer |
| Dominic R. Cundari | Chief Commercial Officer |
Contact
| Address | 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305, United States |
| Phone | 763 496 5454 |
| Website | https://www.diamedica.com |